This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Oosterbaan, D. B. Articles by van Dyck, R. Search for Related Content PubMed PubMed Citation Articles by Oosterbaan, D. B. Articles by van Dyck, R. Social Bookmarking                         What's this?

The placebo response in social phobia

Department of Psychiatry and Institute for Research in Extramural Medicine, Vrije Universiteit, Amsterdam

Anton J. L. M. van Balkom

Department of Psychiatry, Vrije Universiteit, Valeriusplein 9, 1075 BG, Amsterdam, The Netherlands; vanbalkom{at}ggzba.nl

Philip Spinhoven

Department of Psychiatry and Division of Clinical and Health Psychology, Leiden University, Leiden, The Netherlands

Richard van Dyck

Department of Psychiatry and Institute for Research in Extramural Medicine, Vrije Universiteit, Amsterdam

The placebo response forms a growing problem in randomized, placebo-controlled clinical trials in psychiatry. Research into the placebo response is on the increase, but remains very limited in relation to social phobia. Together with the dropout rate, the placebo effect is an important factor limiting the discriminative properties of any study. In this study, we reviewed 15 placebo-controlled studies in social phobia, focussing on patients and study characteristics. In social phobia, the placebo effect has turned out to be moderately large and has shown no increase over the past decade. Placebo response was highest in large, multicentred trials and was independent of study duration. No validation for a placebo run-in was found. Taking into account both response to placebo and active drug, as well as dropout rate, the most discriminative results are probably to be expected in a sample of patients who are moderately to severely impaired. More research in the field of the placebo response is needed.

Key Words: clinical trial • double-blind method • review • placebo • social anxiety disorder • social phobia

Journal of Psychopharmacology, Vol. 15, No. 3, 199-203 (2001)
DOI: 10.1177/026988110101500314


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol, November 1, 2005; 19(6): 567 - 596. [Abstract] [PDF]

				S. Kasper, D. J. Stein, H. Loft, and R. Nil Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study The British Journal of Psychiatry, March 1, 2005; 186(3): 222 - 226. [Abstract] [Full Text] [PDF]